Janux Therapeutics (JANX) Expected to Release Quarterly Earnings on Thursday

Key Points

• Janux Therapeutics is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting a loss of $0.4737 per share and revenue of $8.03 million. A conference call is scheduled for November 6 at 4:00 p.m. ET.
• The company’s prior quarter fell short of expectations, reporting a $0.35 per-share loss versus the projected $0.25 loss and $10.27 million in revenue versus the $19.07 million estimate.
• JANX recently traded at $18.05, up 4.6%, while analysts maintain a “Moderate Buy” consensus and an average price target of $36.46, despite ratings ranging from Strong Buy to Sell.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Janux Therapeutics to announce earnings of ($0.4737) per share and revenue of $8.03 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. On average, analysts expect Janux Therapeutics to post ($1.70) EPS for the current fiscal year and ($2.64) EPS for the next fiscal year.

Janux Therapeutics Stock Up 4.6%

JANX opened at $18.05 on Thursday. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The business has a fifty day simple moving average of $17.59 and a 200-day simple moving average of $15.29. The firm has a market cap of $1.10 billion, a P/E ratio of -11.01 and a beta of 2.40.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JANX. Wolfe Research upgraded Janux Therapeutics from a "peer perform" rating to an "outperform" rating and set a $23.00 target price for the company in a report on Monday, August 24th. Guggenheim cut their price target on shares of Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. TD Cowen raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Janux Therapeutics in a report on Friday, October 16th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Janux Therapeutics in a research note on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $36.46.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company's research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux's proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.